|Bid||6.86 x 800|
|Ask||6.87 x 1000|
|Day's Range||6.80 - 8.35|
|52 Week Range||3.33 - 14.20|
|Beta (3Y Monthly)||3.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 26, 2019 - Aug 30, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.38|
Generic pharmaceutical products provider Lannett Company (LCI) is a puzzle.Lannett shares jumped as much as 50% today, before trimming back some gains to trade up about 40%. Why? Your guess is as good as anybody else’s.SunTrust analyst Gregg Gilbert believes "management has been doing the right things to diversify the business and grow out of the levo trough." However, the analyst remains sidelined on the stock "pending greater visibility on the durability and profitability of the evolving portfolio and strategy to deal with the large debt load." The investigation into generic drug price fixing in the industry gives the analyst another reason to be worried about. But overall, the analyst believes that "this risk has taken more out of generic market caps than seems reasonable."Gilbert rates Lannett stock a Hold along with a $9.00 price target, which implies nearly 7% upside from current levels. (To watch Gilbert's track record, click here)BMO analyst Gary Nachman believes Lannett stock is worth $10 a share, the highest price target of any of the analysts recommending the stock today, though he rates the stock Neutral.Nachman stated, "LCI is executing well trying to manage through Levo loss and base erosion (typically mid-single digits, although some upside there in F2019). New product launches are expected to generate ~$75mm annually (F2019 on track for that), with about half expected from internal R&D and half from inlicensed products. Recently approved AB-rated Methylphenidate with partner Andor (launch late-June) and Thalidomide (addressing CRL, expected launch C2020) should be important contributors. Numbrino approval is expected by year-end, but LCI will cease unapproved C-topical sales ($3mm/qtr.) in August. On cost savings, LCI has completed all necessary actions and will finalize Cody Labs transition soon. LCI is proactively managing debt load (repurchased $24mm in open market, cash ~$205mm) and is confident in maintaining covenant compliance on 2020 debt."Ultimately, TipRanks reveals LCI as a stock that has not drawn a vote of confidence among Wall Street opinion. Out of 5 analysts polled in the last 12 months, all 5 rate the stock Hold/Neutral. Worthy of note, the 12-month average price target stands at $8.33, which aligns evenly with where the stock is currently trading. (See LCI's price targets and analyst ratings on TipRanks) More recent articles from Smarter Analyst: * Buy Facebook (FB) Stock Into Earnings, Says Wedbush * All Eyes on Tesla (TSLA) Stock Ahead of Earnings; Wedbush Remains Neutral * Top Analyst Shares Two Cents on Amazon (AMZN) Stock as Earnings Approach * Curaleaf Helping to Put U.S. Cannabis Sector on the Map
Shares of generic-drug manufacturer Lannett Company Inc. shot up 40% in Monday afternoon trade. The company has not released any news that would account for the stock move, a spokesman for the company said. However, Lannet stock's short interest stood at at 20.66 million shares at the end of June, equal to 74.3% of the company's public float of 27.8 million shares. Ihor Dusaniwsky,managing director for predictive analytics at S3 Partners, a company that tracks short interest, said the move was not caused by a short squeeze, although it could trigger one if the stock keeps rallying. Short positions were down about $128,000 year-to-date, through Friday. "Shorts have taken a good stomach punch today, they're down $46.2 million," he said. "They are definitely a candidate for a short squeeze after today." Shares of Lannett have gained 67.9% in the year to date, while the S&P 500 has gained 19.2%.
HENDERSONVILLE, TN / ACCESSWIRE / July 19, 2019 / The Law Offices of Timothy L. Miles , who has been leading the fight to protect shareholder rights for over 18 years, announces that Lannett Company (NYSE:LCI) ...
On Tuesday morning, Benzinga Pro subscribers received two options alerts related to Lannett. At 9:36 a.m., a trader bought 854 Lannett call options at a $7.50 strike price that expire on Sept. 20. At 9:42 a.m., likely the same trader bought another 752 Sept. 20 $7.50 Lannett call options at the ask price of 45.1 cents.
The federal agency's ruling means its review of Lannett's new drug application for a topical cocaine hydrocholride product can continue.
PHILADELPHIA, July 3, 2019 /PRNewswire/ -- Lannett Company, Inc. (LCI) today commented on the U.S. Food and Drug Administration's (FDA) denial of a Citizen Petition submitted by Genus Lifesciences requesting that the FDA refuse to accept any submissions related to Lannett's 505(b)(2) New Drug Application (NDA) for Cocaine Hydrochloride Topical Solution, 4% and 10%.
How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
Dantrolene Capsules 25 mg, 50 mg and 100 mg is the therapeutic equivalent to the reference listed drug, Dantrium® Capsules 25 mg, 50 mg and 100 mg of Par Pharmaceuticals, Inc. (an Endo International Company). Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products as well as niche generic products.
PHILADELPHIA , June 18, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, the therapeutic ...
PHILADELPHIA , June 12, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced its participation at two upcoming investor conferences. Schedule below: Raymond James 2019 Life Sciences ...
The Northeast Philadelphia generic drug company is co-developing the biosimilar with a Chinese partner.
PHILADELPHIA, June 5, 2019 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced the commencement of a human clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC). The trial, being conducted in South Africa, is the first clinical study to directly compare the Lannett/HEC insulin glargine to US Lantus® as part of the effort to file a biosimilar Biologics License Application with the U.S. Food and Drug Administration. Insulin glargine is a long-acting insulin used to treat adults with Type 2 diabetes, as well as adults and pediatric patients with Type 1 diabetes, for the control of high blood sugar.
NEW YORK , May 30, 2019 /PRNewswire/ -- A.O. Smith Corporation (AOS) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations questioning AOS' access ...
PHILADELPHIA , May 29, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Methylphenidate Hydrochloride Extended Release (ER) tablets USP (CII) in 18 ...
PHILADELPHIA, May 24, 2019 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that the company's chief financial officer (CFO), Martin Galvan, 67, will retire on August 30, 2019, following the planned submission of the company's Form 10-K for fiscal year 2019. Lannett is conducting a search for its next CFO, which includes internal and external candidates, and has retained an executive search firm to assist in the process. "On behalf of the entire Board and management team, I thank Marty for his dedication and valuable contributions over his eight-year career at Lannett," said Tim Crew, chief executive officer of Lannett.
SAN DIEGO, May 23, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential violations of federal and state laws by Lannett Company, Inc. (LCI) ("Lannett") and certain of its officers. In 2017 a securities class action lawsuit was filed on behalf of purchasers of the securities of Lannett from July 15, 2014 and October 31, 2017, (the "Class Period"). The complaint alleges that Defendants made false and misleading statements regarding the Company's drug pricing methodologies and internal controls. On May 15, 2019, Judge Wendy Beetlestone denied defendants motion to dismiss.
PHILADELPHIA , May 23, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Melissa V. Rewolinski , PhD, to its board of directors, effective July 1, 2019 . Following ...
Haeggquist & Eck, LLP, a leading shareholder rights litigation firm, is investigating whether certain officers and directors of Lannett Company, Inc. (“Lannett” or the “Company”) (LCI) breached their fiduciary duties to the Company and its shareholders. Lannett is a generic drug maker that grew quickly starting in 2013, largely due to big price increases. In fact, the price of its generic drug Digoxin, a life-saving heart failure drug, rose 857% from April 2013 to April 2015.
Crew noted that the company's solid financial performance over the last three quarters contributed to its ability to purchase the Term A Loans prior to maturity. In March 2019, the company completed the purchase of approximately $24 million principal amount of its Term A and Term B Loans in open market transactions, bringing the total purchases of its Term Loans to approximately $55 million over the last three months. These amounts are in addition to the company's required annual principal payments of approximately $67 million.
Shareholder rights law firm Robbins Arroyo LLP announces that Lannett Company (LCI) may face damages caused by a pending securities lawsuit action lawsuit. Investors filed a class action complaint against Lannett for alleged violations of the Securities Exchange Act of 1934. Extensive regulatory investigations revealed that Lannett was involved in an industry-wide conspiracy to fix prices and allocate territories for the sale of at least 18 different generic medications.
Bragar Eagel & Squire, P.C. is investigating potential claims against Lannett Company, Inc. (LCI) on behalf of Lannett stockholders. Our investigation concerns whether Lannett has violated the federal securities laws and/or engaged in other unlawful business practices. On May 7, 2019, Lannett filed a Form 10-Q stating that on May 1, 2019, the company and one of its employees received written notice from various state Attorneys General that they intend to bring claims alleging price fixing and anti-competitive behavior with respect to certain drug products, some of which are manufactured and distributed by the company. On this news, Lannett’s stock price fell by more than 15%, closing at $7.19 on May 8, 2019.
PHILADELPHIA, May 16, 2019 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that it has begun marketing a generic version of Adderall®, an immediate-release (IR) mixed salt of a single entity Amphetamine tablet product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate), with strengths of 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg and 30 mg tablets.